Medtronic launches adaptive deep brain stimulation system for Parkinson’s in India

The system is powered by BrainSense technology, which has received approval from USFDA

ProBioGen appoints Dr Simon Johannes Bulling as its new Chief Operating Officer

Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations

US FDA okays Merck's new once-daily HIV pill

The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir

Pfizer unleashes wave of breakthrough cancer data at ASCO 2026

Pharma giant targets new standards of care

Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal to advance cancer treatment

Novo Nordisk’s Etavopivat delivers major Phase 3 win in sickle cell disease

By cutting pain crises & boosting haemoglobin

Merck wins FDA priority review for KEYTRUDA bladder cancer combo expansion

If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev

Astellas & Pfizer win FDA priority review for bladder cancer treatment expansion

A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline

Roche’s MS drug fenebrutinib delivers striking Phase III results by cutting relapse rates by 58%

The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints

ENSPRYNG cuts MOGAD relapse risk by 68% in landmark Phase III trial: Roche

The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents